La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cannabis Suisse a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cannabis Suisse..

Cannabis Suisse (OTC:CSUI) Azioni, Catena delle Opzioni

Cannabis Suisse Corp is engaged in the rental of commercial office and industrial space.

CANNABIS SUISSE CORP by Cannabis Suisse Corp.

Cannabis Suisse Corp

Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) reported quarterly earnings of $1.97 per share which beat the analyst consensus estimate of $1.71 by 15.2 percent. This is a 56.35 percent increase over earnings of $1.26 per share from the same period last year. The company reported quarterly sales of $593.74 million which missed the analyst consensus estimate of $613.63 million by 3.24 percent. This is a 5.96 percent increase over sales of $560.35 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

STRL

Sterling Infrastructure Q3 EPS $1.97 Beats $1.71 Estimate, Sales $593.74M Miss $613.63M Estimate

Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.06) by 100 percent. The company reported quarterly sales of $122.751 million which missed the analyst consensus estimate of $125.853 million by 2.47 percent. This is a 3.99 percent decrease over sales of $127.854 million the same period last year.

NDLS

Noodles Q3 2024 Adj. EPS $(0.12) Misses $(0.06) Estimate, Sales $122.751M Miss $125.853M Estimate

Crane NXT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXT#NYSE">CXT</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.14 by 1.75 percent. The company reported quarterly sales of $403.500 million which beat the analyst consensus estimate of $392.440 million by 2.82 percent. This is a 14.34 percent increase over sales of $352.900 million the same period last year.

Crane NXT Q3 2024 Adj. EPS $1.16 Beats $1.14 Estimate, Sales $403.500M Beat $392.440M Estimate

Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.17) by 29.41 percent.

Brookdale Senior Living Q3 2024 Adj. EPS $(0.22) Misses $(0.17) Estimate

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) raises FY2024 sales outlook from $432.00 million-438.00 million to $442.00 million-445.00 million.

Guidance

VCYT

Veracyte Raises FY2024 Sales Guidance from $432.00M-438.00M to $442.00M-445.00M  VS Est. 436.14M

CLNE

Clean Energy Fuels Sees FY24 Adj. EBITDA $62M-$72M

VIZIO Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZIO#NYSE">VZIO</a>) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.02) by 105 percent. The company reported quarterly sales of $444.70 million which beat the analyst consensus estimate of $443.80 million by 0.20 percent. This is a 4.34 percent increase over sales of $426.20 million the same period last year.

VZIO

VIZIO Holding Q3 2024 GAAP EPS $0.00 Beats $(0.02) Estimate, Sales $444.70M Beat $443.80M Estimate

LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) raises FY2025 sales outlook from $715.00 million-735.00 million to $737.00 million-739.00 million.

RAMP

LiveRamp Holdings Raises FY2025 Sales Guidance from $715.00M-735.00M to $737.00M-739.00M

Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. The company reported quarterly sales of $330.99 million which missed the analyst consensus estimate of $346.28 million by 4.42 percent. This is a 8.16 percent increase over sales of $306.03 million the same period last year.

CLOV

Clover Health Investments Q3 2024 GAAP EPS $(0.02) Beats $(0.04) Estimate, Sales $330.99M Miss $346.28M Estimate

LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) sees Q3 sales of $191.000 million vs $188.55 million estimate.

LiveRamp Holdings Sees Q3 Sales $191.000M vs $188.55M Est

Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.46) by 19.57 percent. This is a 89.66 percent decrease over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $1.39 million which missed the analyst consensus estimate of $1.48 million by 6.01 percent. This is a 30.98 percent increase over sales of $1.06 million the same period last year.

NYXH

Nyxoah Q3 EPS $(0.55) Misses $(0.46) Estimate, Sales $1.39M Miss $1.48M Estimate

Retail Sales

FTEK

Fuel Tech Inc Announced Orders From New And Existing Customers Totaling ~$2M

e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) shares are climbing after the company reported its second-quarter results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/b41786513/e-l-f-beauty-announces-second-quarter-fiscal-2025-results">details from the report.  </a>
The Details: e.l.f. Beauty reported quarterly earnings of 77 cents per share, which beat the analyst consensus estimate of 42 cents. Quarterly revenue came in at $301.1 million, which beat the analyst consensus estimate of $285.76 million and is an increase over sales of $215.5 million from the same period last year.
e.l.f. said its gross margin increased approximately 40 basis points to 71%, primarily driven by cost savings, favorable foreign exchange impacts and price increases in the company&#8217;s international markets, partially offset by mix and higher transportation costs.
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
&#8220;Q2 marked another quarter of consistent, category-leading growth. In Q2, we delivered 40% net sales growth, fueled by 195 basis points of market share gains in the U.S. and 91% net sales growth internationally,&#8221; said Tarang Amin, e.l.f. Beauty&#8217;s CEO.
&#8220;This was our 23rd consecutive quarter of both net sales growth and market share gains. We continue to make progress across color cosmetics, skincare and international and believe our unique areas of advantage will fuel our ability to win in fiscal 2025 and beyond,&#8221; Amin added.
Outlook: e.l.f. Beauty raised its fiscal year 2025 net sales outlook to a range of $1.315 billion to $1.335 billion and now sees earnings of between $3.47 and $3.53 per share for the year.
ELF Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, e.l.f. Beauty shares are up 13.24% after-hours at $117.95 at the time of publication Wednesday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Photo: Courtesy of E.l.f. Beauty, Inc.

Movers

e.l.f. Beauty Stock Soars After Strong Q2 Earnings Beat: Details

Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 by 20 percent. The company reported quarterly sales of $315.119 million which beat the analyst consensus estimate of $310.218 million by 1.58 percent. This is a 28.75 percent decrease over sales of $442.291 million the same period last year.

CCRN

Cross Country Healthcare Q3 2024 Adj. EPS $0.12 Beats $0.10 Estimate, Revenue From Services $315.119M Beat $310.218M Estimate

GFL Environmental Q3 2024 Adj. EPS C$0.23 Misses C$0.35 Estimate, Sales C$2.015B Miss C$2.052B Estimate

Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.42 by 2.38 percent. The company reported quarterly sales of $2.653 billion which beat the analyst consensus estimate of $2.485 billion by 6.76 percent. This is a 3.67 percent increase over sales of $2.559 billion the same period last year.

Williams Companies Q3 2024 Adj. EPS $0.43 Beats $0.42 Estimate, Sales $2.653B Beat $2.485B Estimate

CS Disco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAW#NYSE">LAW</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $36.27 million which missed the analyst consensus estimate of $36.33 million by 0.18 percent. This is a 3.79 percent increase over sales of $34.94 million the same period last year.

CS Disco Q3 Adj $(0.06) Beats $(0.09) Estimate, Sales $36.27M Miss $36.33M Estimate

Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) raises FY2024 sales outlook from $1.05 billion-1.13 billion to $1.06 billion-1.13 billion.

Emergent BioSolutions Raises FY2024 Sales Guidance from $1.05B-1.13B to $1.06B-1.13B

Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) reported quarterly earnings of $1.80 per share which beat the analyst consensus estimate of $1.57 by 14.65 percent. The company reported quarterly sales of $1.305 billion which beat the analyst consensus estimate of $1.267 billion by 3.01 percent. This is a 10.03 percent increase over sales of $1.186 billion the same period last year.

Comments

Cannabis Suisse

Cannabis Suisse (CSUI) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO